Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
Status:
Terminated
Trial end date:
2020-07-02
Target enrollment:
Participant gender:
Summary
This is an open label nonrandomized Phase I/ IIA trial designed to assess the safety,
tolerability, and efficacy of apatinib in combination with pembrolizumab. Phase I will assess
the safety of combining increasing oral daily doses of apatinib with a fixed dose of IV
pembrolizumab every three weeks and will determine the RP2D (Recommended Phase 2 Dose). Phase
II will assess the efficacy of the RP2D of apatinib in combination with pembrolizumab and
provide additional safety and tolerability data in three disease-specific cohorts